Lentitek
Edinburgh, GB · 2 known investors
Find your way into Lentitek
1,128 people in our graph share verified history with the Lentitek team — schools, employers, funds. One of them is your warm intro.
Deji Sasegbonunlockedknows John Counsell · together at Imperial College London (overlapped)
×5knows the team · via University of Oxford
knows the team · via Deep Science Ventures
knows the team · via Imperial College London
×3knows the team · via University of St Andrews
knows the team · via University of York
Lentitek develops an alternative lentiviral vector production platform based on novel synthetic promoter technology, aimed at improving quality and yield in CAR-T manufacture and enabling in-vivo and armoured CAR applications. It works with advanced therapy (ATMP) asset developers through a serviced CRO license model to integrate and validate its vector solution.
Founders & leadership
AI
Adam IncheinFounderHe has background in protein structure and cell biology, and held prior commercial roles in biomanufacturing before founding the company with Leif Anderson in 2019.
L
LeifCo-founder / Board member
JC
John CounsellinChief Scientific OfficerJohn Counsell leads academic research at UCL in genetic engineering and therapeutic delivery, and serves as Chief Scientific Officer of Lentitek, a lentiviral vector technology company. He also advises Deep Science Ventures on synthetic biology and gene therapy startups.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- LENTITEK LTD
- Company number
- SC633239
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 12 Jun 2019
- Registered office
- Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA
- Nature of business (SIC)
- 21100 — Manufacture of basic pharmaceutical products71200 — Technical testing and analysis72110 — Research and experimental development on biotechnology74909 — Other professional, scientific and technical activities n.e.c.
- Accounts
- last made up to 30 Jun 2025 · next due 31 Mar 2027
- Confirmation statement
- last made up to 3 Jul 2026 · next due 17 Jul 2027
Current officers · 3
- Leif Crombie Anderson — director, appointed 5 Jun 2021
- Adam Grant Inche — director, appointed 12 Jun 2019
- Michael Lesley Roberts — director, appointed 29 Jul 2024
Source: Companies House public register · retrieved 5 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Lentitek raises funds for cell and gene therapy – Daily Businessdailybusinessgroup.co.uk · Aug 2026Frequently asked questions
- What does Lentitek do?
- Lentitek develops an alternative lentiviral vector production platform based on novel synthetic promoter technology, aimed at improving quality and yield in CAR-T manufacture and enabling in-vivo and armoured CAR applications. It works with advanced therapy (ATMP) asset developers through a serviced CRO license model to integrate and validate its vector solution.
- Who founded Lentitek?
- Lentitek was founded by Adam Inche, Leif.
- Who are Lentitek's investors?
- Lentitek's investors include Apollo Informal Investment, Equity Gap.
- Where is Lentitek headquartered?
- Lentitek is headquartered in Edinburgh, GB.